Archives
International Journal of Zoology and Applied Biosciences Research Article
Clinical study of efficacy and side effects profile of bevacizumab drug in different types of cancer patients
Chinta Vaishnavi, D. Swathi, V. Umarani and K. Shravan Kumar
Year : 2026 | Volume: 11 | Issue: 3 | Pages: 60-66
Received on: 21/01/2026
Revised on: 12/02/2026
Accepted on: 17/03/2026
Published on: 01/05/2026
-
Chinta Vaishnavi, D. Swathi, V. Umarani and K. Shravan Kumar( 2026).
Clinical study of efficacy and side effects profile of bevacizumab drug in different types of cancer patients
. International Journal of Zoology and Applied Biosciences, 11( 3), 60-66.
-
click to view the cite format
Abstract
Cancer is a major global health challenge characterized by uncontrolled cellular proliferation, invasion of surrounding tissues, and metastasis to distant organs. Targeting angiogenesis has emerged as an effective therapeutic strategy in cancer treatment. Bevacizumab, a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF), inhibits tumor angiogenesis by preventing VEGF from binding to its receptors on endothelial cells. The present study aimed to evaluate the efficacy and safety profile of bevacizumab in patients with different types of cancers treated at a tertiary care hospital. A prospective, single-arm observational study was conducted on 168 adult cancer patients receiving bevacizumab either as monotherapy or in combination with chemotherapy or immunotherapy. Clinical outcomes, progression-free survival (PFS), adverse drug reactions, and quality-of-life parameters were assessed during the study period. The results demonstrated that 63.1% of patients achieved clinical benefit (complete response, partial response, or stable disease), with a median PFS of approximately 8.4 months. Quality-of-life improvement was reported by nearly 70% of patients. Adverse effects were observed in 37.5% of cases, with hypertension, proteinuria, and thromboembolic events being the most common serious adverse reactions. Most side effects were manageable with appropriate monitoring and supportive care. The findings suggest that bevacizumab provides meaningful therapeutic benefits with an acceptable safety profile in patients with various malignancies. Careful patient selection and vigilant monitoring remain essential to optimize treatment outcomes and minimize treatment-related toxicities.
Keywords
Bevacizumab, Angiogenesis inhibition, Safety profile, Cancer treatment, Targeted therapy.
-
Full Article PDF (
77)
- View HTML Article
Copy Rights
© The Author(s) 2025. This article is published by International Journal of Zoology and Applied Biosciences under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
